Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Cytoreduction Regimens

Thiotepa/cyclophosphamide/TBI as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome

Bone Marrow Transplantation volume 33, pages 789–792 (2004)Cite this article

Summary:

In all, 18 patients (30–56 years; median 49) with MDS underwent allogeneic HSCT from related (n=12) or unrelated (n=6) donors after a conditioning regimen comprising thiotepa, cyclophosphamide, and TBI. GVHD prophylaxis consisted of cyclosporine (n=15) or tacrolimus (n=3) with short-course methotrexate. Four patients had low-risk disease (refractory anemia or complete remission after chemotherapy) and 14 patients had high-risk disease (RAEB, RAEB-t, or AML). Grade II–IV acute GVHD developed in six patients and chronic GVHD in 10. With a median follow-up of 31 months, the 2-year survival probability is 75% for low-risk patients and 57% for high-risk patients. One patient died of leukemia and six of treatment-related causes. This conditioning regimen requires further study in patients with MDS.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Luger S, Sacks N . Bone marrow transplantation for myelodysplastic syndrome – who? when? and which? Bone Marrow Transplant 2002; 30: 199–206.

    Article  CAS  PubMed  Google Scholar 

  2. Appelbaum FR, Anderson J . Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia 1998; 12 (Suppl. 1): S25–S29.

    PubMed  Google Scholar 

  3. Sierra J, Perez WS, Rozman C et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 2002; 100: 1997–2004.

    CAS  PubMed  Google Scholar 

  4. Anderson JE . Allogeneic hematopoietic cell transplantation for myelodysplastic and myeloproliferative disorders. In: Thomas ED, Blume KG, Forman SJ (eds). Hematopoietic Cell Transplantation, 2 edn. Blackwell Scientific: Oxford, 1999; pp 872–886.

    Google Scholar 

  5. Zecca M, Pession A, Messina C et al. Total body irradiation, thiotepa, and cyclophosphamide as a conditioning regimen for children with acute lymphoblastic leukemia in first or second remission undergoing bone marrow transplantation with HLA-identical siblings. J Clin Oncol 1999; 17: 1838–1846.

    Article  CAS  PubMed  Google Scholar 

  6. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562–1568.

    Article  CAS  PubMed  Google Scholar 

  7. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295–304.

    Article  CAS  PubMed  Google Scholar 

  8. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.

    Article  CAS  PubMed  Google Scholar 

  9. Castagna L, Weshi EA, Bourhis JH et al. Successful donor lymphocyte infusion (DLI) in a patient with myelodysplastic syndrome (MDS) after failure of T-cell-depleted bone marrow transplantation (TD-BMT). Br J Hematol 1998; 103: 284–285.

    Article  CAS  Google Scholar 

  10. Shiobara S, Nakao S, Ueda M et al. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome. Bone Marrow Transplant 2000; 26: 769–774.

    Article  CAS  PubMed  Google Scholar 

  11. Kroger N, Schetelig J, Zabelina T et al. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. Bone Marrow Transplant 2001; 28: 643–647.

    Article  CAS  PubMed  Google Scholar 

  12. Rezvani K, Lalancette M, Szydlo R et al. Non-myeloablative stem cell transplant in AML, ALL, and MDS: disappointing outcome for patients with advanced phase disease. Blood 2000; 96 (Suppl): 2061.

    Google Scholar 

  13. Locatelli F, Niemeyer C, Angelucci E et al. Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: a report from the European Working Group on myelodysplastic syndrome in childhood. J Clin Oncol 1997; 15: 566–573.

    Article  CAS  PubMed  Google Scholar 

  14. Ratannatharthorn V, Karanes C, Uberti J et al. Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Blood 1993; 81: 2194–2199.

    Google Scholar 

  15. Anderson JE, Appelbaum FR, Schoch G et al. Allogeneic marrow transplantation for myelodisplastic syndrome with advanced disease morphology: a phase II study of buslfan, cyclophosphamide, and total body irradiation and analysis of prognostic factors. J Clin Oncol 1996; 14: 220–226.

    Article  CAS  PubMed  Google Scholar 

  16. Egorin MJ, Snyder SW, Pan SS et al. Cellular transport and accumulation of thiotepa in murine, human, and avian cells. Cancer Res 1989; 49: 5611–5617.

    CAS  PubMed  Google Scholar 

  17. Egorin MJ, Snyder SW, Pan SS et al. Cellular transport and accumulation of thiotepa. Semin Oncol 1990; 17: 7–17.

    CAS  PubMed  Google Scholar 

  18. Egorin MJ, Snyder SW, Wietharn BE et al. Effects of ethanolamine and choline on thiotepa cellular accumulation and cytotoxicity in L1210 cells. Cancer Res 1990; 50: 4322–4327.

    CAS  PubMed  Google Scholar 

  19. Wolff SN, Herzig RH, Fay JW et al. High-dose N,N′,N″-triethylenthiophosphoramide(thiotepa) with autologous bone marrow transplantation: phase I studies. Semin Oncol 1990; 17 (Suppl. 3): 2–6.

    CAS  PubMed  Google Scholar 

  20. Papadopoulos EB, Carabasi MH, Castro-Malaspina H et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood 1998; 91: 1083–1090.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. First Department of Internal Medicine, Yokohama City University School of Medicine, Yokohama, Japan

    K Fujimaki, S Fujisawa, H Kanamori & Y Ishigatsubo

  2. Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan

    J Taguchi, H Fujita, M Hattori, E Yamazaki, N Takahashi & A Maruta

Authors
  1. K Fujimaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Taguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Fujita
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Hattori
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E Yamazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Fujisawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H Kanamori
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A Maruta
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Y Ishigatsubo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K Fujimaki.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fujimaki, K., Taguchi, J., Fujita, H. et al. Thiotepa/cyclophosphamide/TBI as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. Bone Marrow Transplant 33, 789–792 (2004). https://doi.org/10.1038/sj.bmt.1704451

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704451

Keywords

This article is cited by

Search

Advanced search

Quick links